FDA Purple Book · Reference family
vedolizumab (Entyvio)
vedolizumab is an FDA-licensed reference biologic from Takeda Pharmaceuticals U.S.A., Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
351(a)BLA 761133
Entyvio vedolizumab
Takeda Pharmaceuticals U.S.A., Inc.
- Approved
- Sep 27, 2023
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for vedolizumab, in chronological order.
Reference approval
Approval date of the reference vedolizumab product.
2 yr 9 mo ago
Frequently asked questions
Are there biosimilars approved for vedolizumab (Entyvio)?
No 351(k) biosimilars or interchangeable biosimilars referencing vedolizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.